Enliven Therapeutics (Nasdaq:
ELVN) has appointed Rick (Richard) Fair as its new Chief Executive Officer and member of the Board of Directors, effective December 11, 2025.135
Former CEO and co‑founder Sam Kintz is transitioning to the role of Head of Pipeline, where he will focus on early-stage research programs and advancing pipeline assets into the clinic.14
The leadership change is explicitly tied to Enliven’s preparations for a planned pivotal Phase 3 trial of ELVN‑001 for chronic myeloid leukemia (CML), which the company intends to initiate in 2026.135
Rick Fair brings extensive late-stage oncology and hematology commercialization experience, having previously overseen launches and commercialization planning for a large oncology/hematology portfolio estimated at about $23 billion.1
The Board highlighted that Enliven is well-capitalized, with reported cash of approximately $477.6 million and financial runway expected into the first half of 2029, supporting the next phase of clinical and commercial development.1
Enliven has also approved inducement equity grants for the new CEO, including an option covering 875,000 shares of common stock at an exercise price of $18.77 per share, granted under Nasdaq’s inducement grant exception.2
Company leadership emphasized that keeping co‑founder Sam Kintz in a senior R&D role preserves program continuity for ELVN‑001 and the broader early pipeline while leveraging Fair’s commercialization background for the upcoming Phase 3 and potential market launch.13
Sources:
1. https://www.stocktitan.net/news/ELVN/enliven-therapeutics-announces-new-ceo-to-drive-next-phase-of-shnp0v50uman.html
2. https://www.stocktitan.net/news/ELVN/enliven-therapeutics-reports-inducement-grants-as-permitted-by-the-k9cornvas4qe.html
3. https://www.gurufocus.com/news/3245270/enliven-elvn-appoints-new-ceo-as-it-prepares-for-phase-3-trial
4. https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3XH13P:0-enliven-therapeutics-appoints-rick-fair-as-new-ceo-shares-down/
5. https://www.tipranks.com/news/company-announcements/enliven-therapeutics-appoints-richard-fair-as-ceo